메뉴 건너뛰기




Volumn 392, Issue 10162, 2018, Pages 2367-2377

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

(17)  Mease, Philip a,b   Coates, Laura C c   Helliwell, Philip S d   Stanislavchuk, Mykola e   Rychlewska Hanczewska, Anna f   Dudek, Anna g   Abi Saab, Walid h   Tasset, Chantal h   Meuleners, Luc h   Harrison, Pille h   Besuyen, Robin i   Van der Aa, Annegret h   Mozaffarian, Neelufar j   Greer, Joy M j   Kunder, Rebecca j   Van den Bosch, Filip k,l   Gladman, Dafna D m  


Author keywords

[No Author keywords available]

Indexed keywords

FILGOTINIB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

EID: 85055135028     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32483-8     Document Type: Article
Times cited : (171)

References (32)
  • 1
    • 84945438141 scopus 로고    scopus 로고
    • The epidemiology of psoriatic arthritis
    • Ogdie, A, Weiss, P, The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41 (2015), 545–568.
    • (2015) Rheum Dis Clin North Am , vol.41 , pp. 545-568
    • Ogdie, A.1    Weiss, P.2
  • 2
    • 14244260176 scopus 로고    scopus 로고
    • Psoriatic arthritis: epidemiology, clinical features, course, and outcome
    • Gladman, DD, Antoni, C, Mease, P, Clegg, DO, Nash, P, Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (2005), ii14–ii17.
    • (2005) Ann Rheum Dis , vol.64 , pp. ii14-ii17
    • Gladman, D.D.1    Antoni, C.2    Mease, P.3    Clegg, D.O.4    Nash, P.5
  • 4
    • 85037581361 scopus 로고    scopus 로고
    • The effects of structural damage on functional disability in psoriatic arthritis
    • Kerschbaumer, A, Baker, D, Smolen, JS, Aletaha, D, The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis 76 (2017), 2038–2045.
    • (2017) Ann Rheum Dis , vol.76 , pp. 2038-2045
    • Kerschbaumer, A.1    Baker, D.2    Smolen, J.S.3    Aletaha, D.4
  • 5
    • 85046841562 scopus 로고    scopus 로고
    • Quality of life in psoriatic arthritis
    • Gudu, T, Gossec, L, Quality of life in psoriatic arthritis. Exp Rev Clin Immunol 14 (2018), 405–417.
    • (2018) Exp Rev Clin Immunol , vol.14 , pp. 405-417
    • Gudu, T.1    Gossec, L.2
  • 6
    • 85041908087 scopus 로고    scopus 로고
    • Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review
    • D'Angiolella, LS, Cortesi, PA, Lafranconi, A, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. PharmacoEconomics 36 (2018), 567–589.
    • (2018) PharmacoEconomics , vol.36 , pp. 567-589
    • D'Angiolella, L.S.1    Cortesi, P.A.2    Lafranconi, A.3
  • 7
    • 84936989259 scopus 로고    scopus 로고
    • The indirect costs of psoriatic arthritis: systematic review and meta-analysis
    • Kawalec, P, Malinowski, KP, The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 15 (2015), 125–132.
    • (2015) Expert Rev Pharmacoecon Outcomes Res , vol.15 , pp. 125-132
    • Kawalec, P.1    Malinowski, K.P.2
  • 8
    • 84960126976 scopus 로고    scopus 로고
    • European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
    • Gossec, L, Smolen, JS, Ramiro, S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75 (2016), 499–510.
    • (2016) Ann Rheum Dis , vol.75 , pp. 499-510
    • Gossec, L.1    Smolen, J.S.2    Ramiro, S.3
  • 9
    • 84959912573 scopus 로고    scopus 로고
    • Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis
    • Coates, LC, Kavanaugh, A, Mease, PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68 (2016), 1060–1071.
    • (2016) Arthritis Rheumatol , vol.68 , pp. 1060-1071
    • Coates, L.C.1    Kavanaugh, A.2    Mease, P.J.3
  • 10
    • 85016812795 scopus 로고    scopus 로고
    • Switching biologics in the treatment of psoriatic arthritis
    • Merola, JF, Lockshin, B, Mody, EA, Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 47 (2017), 29–37.
    • (2017) Semin Arthritis Rheum , vol.47 , pp. 29-37
    • Merola, J.F.1    Lockshin, B.2    Mody, E.A.3
  • 11
    • 84899083985 scopus 로고    scopus 로고
    • Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
    • Lebwohl, MG, Bachelez, H, Barker, J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70 (2014), 871–881.
    • (2014) J Am Acad Dermatol , vol.70 , pp. 871-881
    • Lebwohl, M.G.1    Bachelez, H.2    Barker, J.3
  • 13
    • 77955375143 scopus 로고    scopus 로고
    • Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
    • Meyer, DM, Jesson, MI, Li, X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm, 7, 2010, 41.
    • (2010) J Inflamm , vol.7 , pp. 41
    • Meyer, D.M.1    Jesson, M.I.2    Li, X.3
  • 14
    • 85031767309 scopus 로고    scopus 로고
    • Tofacitinib or adalimumab versus placebo for psoriatic arthritis
    • Mease, P, Hall, S, FitzGerald, O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377 (2017), 1537–1550.
    • (2017) N Engl J Med , vol.377 , pp. 1537-1550
    • Mease, P.1    Hall, S.2    FitzGerald, O.3
  • 15
    • 85031800565 scopus 로고    scopus 로고
    • Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors
    • Gladman, D, Rigby, W, Azevedo, VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377 (2017), 1525–1536.
    • (2017) N Engl J Med , vol.377 , pp. 1525-1536
    • Gladman, D.1    Rigby, W.2    Azevedo, V.F.3
  • 16
    • 85043338932 scopus 로고    scopus 로고
    • Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis
    • Wu, D, Yue, J, Tam, LS, Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology 57 (2018), 563–571.
    • (2018) Rheumatology , vol.57 , pp. 563-571
    • Wu, D.1    Yue, J.2    Tam, L.S.3
  • 17
    • 84885103906 scopus 로고    scopus 로고
    • Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases
    • Van Rompaey, L, Galien, R, van der Aar, EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 191 (2013), 3568–3577.
    • (2013) J Immunol , vol.191 , pp. 3568-3577
    • Van Rompaey, L.1    Galien, R.2    van der Aar, E.M.3
  • 18
    • 85055096499 scopus 로고    scopus 로고
    • OP0161 the JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis
    • Robin-Jagerschmidt, C, Lavazais, S, Marsais, F, et al. OP0161 the JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis. Ann Rheum Dis 76 (2017), 118–119.
    • (2017) Ann Rheum Dis , vol.76 , pp. 118-119
    • Robin-Jagerschmidt, C.1    Lavazais, S.2    Marsais, F.3
  • 19
    • 85007190313 scopus 로고    scopus 로고
    • Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
    • Kavanaugh, A, Kremer, J, Ponce, L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76 (2017), 1009–1019.
    • (2017) Ann Rheum Dis , vol.76 , pp. 1009-1019
    • Kavanaugh, A.1    Kremer, J.2    Ponce, L.3
  • 20
    • 85007236113 scopus 로고    scopus 로고
    • Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
    • Westhovens, R, Taylor, PC, Alten, R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76 (2017), 998–1008.
    • (2017) Ann Rheum Dis , vol.76 , pp. 998-1008
    • Westhovens, R.1    Taylor, P.C.2    Alten, R.3
  • 21
    • 85044253176 scopus 로고    scopus 로고
    • Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
    • Genovese, M, Westhovens, R, Meuleners, L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther, 20, 2018, 57.
    • (2018) Arthritis Res Ther , vol.20 , pp. 57
    • Genovese, M.1    Westhovens, R.2    Meuleners, L.3
  • 22
    • 85008324875 scopus 로고    scopus 로고
    • Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
    • Vermeire, S, Schreiber, S, Petryka, R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389 (2017), 266–275.
    • (2017) Lancet , vol.389 , pp. 266-275
    • Vermeire, S.1    Schreiber, S.2    Petryka, R.3
  • 23
    • 85055083813 scopus 로고    scopus 로고
    • Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
    • published online Oct 22.
    • van der Heijde, D, Baraliakos, X, Gensler, LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet, 2018 published online Oct 22. http://dx.doi.org/10.1016/S0140-6736(18)32463-2.
    • (2018) Lancet
    • van der Heijde, D.1    Baraliakos, X.2    Gensler, L.S.3
  • 24
    • 33746951437 scopus 로고    scopus 로고
    • Classification criteria for psoriatic arthritis: development of new criteria from a large international study
    • Taylor, W, Gladman, D, Helliwell, P, Marchesoni, A, Mease, P, Mielants, H, Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006), 2665–2673.
    • (2006) Arthritis Rheum , vol.54 , pp. 2665-2673
    • Taylor, W.1    Gladman, D.2    Helliwell, P.3    Marchesoni, A.4    Mease, P.5    Mielants, H.6
  • 25
    • 80155181447 scopus 로고    scopus 로고
    • Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction
    • Mease, PJ, Woolley, JM, Bitman, B, Wang, BC, Globe, DR, Singh, A, Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38 (2011), 2461–2465.
    • (2011) J Rheumatol , vol.38 , pp. 2461-2465
    • Mease, P.J.1    Woolley, J.M.2    Bitman, B.3    Wang, B.C.4    Globe, D.R.5    Singh, A.6
  • 26
    • 84908370285 scopus 로고    scopus 로고
    • Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis
    • Winthrop, KL, Yamanaka, H, Valdez, H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66 (2014), 2675–2684.
    • (2014) Arthritis Rheumatol , vol.66 , pp. 2675-2684
    • Winthrop, K.L.1    Yamanaka, H.2    Valdez, H.3
  • 27
    • 85055117538 scopus 로고    scopus 로고
    • FDA Briefing document. NDA 207924 Baricitnib, a Janus kinase (JAK) inhibitor for RA
    • (Accessed 28 August 2018)
    • US Food and Drug Administration. FDA Briefing document. NDA 207924 Baricitnib, a Janus kinase (JAK) inhibitor for RA. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm605061.pdf, 2018. (Accessed 28 August 2018)
    • (2018)
  • 28
    • 85016146867 scopus 로고    scopus 로고
    • Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
    • D'Angelo, S, Tramontano, G, Gilio, M, Leccese, P, Olivieri, I, Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol 9 (2017), 21–28.
    • (2017) Open Access Rheumatol , vol.9 , pp. 21-28
    • D'Angelo, S.1    Tramontano, G.2    Gilio, M.3    Leccese, P.4    Olivieri, I.5
  • 29
    • 85047254944 scopus 로고    scopus 로고
    • Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
    • Mease, P, van der Heijde, D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 77 (2018), 890–897.
    • (2018) Ann Rheum Dis , vol.77 , pp. 890-897
    • Mease, P.1    van der Heijde, D.2    Landewé, R.3
  • 30
    • 84984629205 scopus 로고    scopus 로고
    • Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
    • Mease, PJ, van der Heijde, D, Ritchlin, CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76 (2017), 79–87.
    • (2017) Ann Rheum Dis , vol.76 , pp. 79-87
    • Mease, P.J.1    van der Heijde, D.2    Ritchlin, C.T.3
  • 31
    • 85046358073 scopus 로고    scopus 로고
    • Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
    • Nash, P, Ohson, K, Walsh, J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77 (2018), 690–698.
    • (2018) Ann Rheum Dis , vol.77 , pp. 690-698
    • Nash, P.1    Ohson, K.2    Walsh, J.3
  • 32
    • 85051453963 scopus 로고    scopus 로고
    • Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
    • Wells, AF, Edwards, CJ, Kivitz, AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology 57 (2018), 1253–1263.
    • (2018) Rheumatology , vol.57 , pp. 1253-1263
    • Wells, A.F.1    Edwards, C.J.2    Kivitz, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.